{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:26:01Z","timestamp":1762100761735,"version":"3.40.5"},"reference-count":68,"publisher":"American Academy of Pediatrics (AAP)","issue":"Supplement_1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,1,1]]},"abstract":"<jats:p>BACKGROUND. Economic assessments that guide policy making on immunizations are becoming increasingly important in light of new and anticipated vaccines for adolescents. However, important considerations that limit the utility of these assessments, such as the diversity of approaches used, are often overlooked and should be better understood.<\/jats:p><jats:p>OBJECTIVE. Our goal was to examine economic studies of adolescent vaccines and compare cost-effectiveness outcomes among studies on a particular vaccine, across adolescent vaccines, and between new adolescent vaccines versus vaccines that are recommended for young children.<\/jats:p><jats:p>METHODS. A systematic review of economic studies on immunizations for adolescents was conducted. Studies were identified by searching the Medline, Embase, and EconLit databases. Each study was reviewed for appropriateness of model design, baseline setup, sensitivity analyses, and input variables (ie, epidemiologic, clinical, cost, and quality-of-life impact). For comparison, the cost-effectiveness outcomes reported in key studies on vaccines for younger children were selected.<\/jats:p><jats:p>RESULTS. Vaccines for healthy adolescents were consistently found to be more costly than the health care or societal cost savings they produced and, in general, were less cost-effective than vaccines for younger children. Among the new vaccines, pertussis and human papillomavirus vaccines were more cost-effective than meningococcal vaccines. Including herd-immunity benefits in studies significantly improved the cost-effectiveness estimates for new vaccines. Differences in measurements or assumptions limited further comparisons.<\/jats:p><jats:p>CONCLUSION. Although using the new adolescent vaccines is unlikely to be cost-saving, vaccination programs will result in sizable health benefits.<\/jats:p>","DOI":"10.1542\/peds.2007-1115h","type":"journal-article","created":{"date-parts":[[2008,1,3]],"date-time":"2008-01-03T16:53:24Z","timestamp":1199379204000},"page":"S63-S78","source":"Crossref","is-referenced-by-count":23,"title":["Projected Cost-effectiveness of New Vaccines for Adolescents in the United States"],"prefix":"10.1542","volume":"121","author":[{"given":"Ismael R.","family":"Ortega-Sanchez","sequence":"first","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace M.","family":"Lee","sequence":"additional","affiliation":[{"name":"Center for Child Health Care Studies, Department of Ambulatory Care and Prevention, Harvard Pilgrim Health Care and Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Infectious Diseases, Children's Hospital Boston, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Jake","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Capitol Outcomes Research, Inc, Alexandria, Virginia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa A.","family":"Prosser","sequence":"additional","affiliation":[{"name":"Center for Child Health Care Studies, Department of Ambulatory Care and Prevention, Harvard Pilgrim Health Care and Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noelle-Angelique","family":"Molinari","sequence":"additional","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinzhi","family":"Zhang","sequence":"additional","affiliation":[{"name":"National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William B.","family":"Baine","sequence":"additional","affiliation":[{"name":"Center for Outcomes and Evidence, Agency for Healthcare Research and Quality, Department of Health and Human Services, Rockville, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary M.","family":"McCauley","sequence":"additional","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ted","family":"Miller","sequence":"additional","affiliation":[{"name":"Pacific Institute for Research and Evaluation, Calverton, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Working Group on Leading Economic Issues for New Vaccine for Adolescents","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2008,1,1]]},"reference":[{"key":"2021120823295659900_R1","unstructured":"Centers for Disease Control and Prevention. Achievements in public health, 1900\u20131999 impact of vaccines universally recommended for children: United States, 1990\u20131998. MMWR Morb Mortal Wkly Rep.\u20081999;48:243\u2013248"},{"key":"2021120823295659900_R2","doi-asserted-by":"crossref","unstructured":"Zhou F, Santoli J, Messonnier ML, et al. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001. Arch Pediatr Adolesc Med.\u20082005;159:1136\u20131144","DOI":"10.1001\/archpedi.159.12.1136"},{"key":"2021120823295659900_R3","doi-asserted-by":"crossref","unstructured":"Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996","DOI":"10.1093\/oso\/9780195108248.001.0001"},{"key":"2021120823295659900_R4","unstructured":"Cohen R, Bloom B. Trends in health insurance and access to medical care for children under age 19 years: United States, 1998\u20132003. Adv Data.\u20082005;(355):1\u201312"},{"key":"2021120823295659900_R5","doi-asserted-by":"crossref","unstructured":"Miller TR, Levy DT. Cost outcome analysis in injury prevention and control: a primer on methods. Inj Prev.\u20081997;3:288\u2013293","DOI":"10.1136\/ip.3.4.288"},{"key":"2021120823295659900_R6","doi-asserted-by":"crossref","unstructured":"Molla MT, Wagener DK, Madans JH. Summary measures of population health: methods for calculating healthy life expectancy. Healthy People 2010 Stat Notes.\u20082001;(21):1\u201311","DOI":"10.1037\/e583762012-001"},{"key":"2021120823295659900_R7","unstructured":"Schwartz B, Ortega-Sanchez IR. Economic analyses of vaccines and vaccination programs. In: Levine MM, Woodrow GC, Kaper JB, Cobon GA, eds. New Generation Vaccines. New York, NY: Marcel Dekker, 2004:107\u2013115"},{"key":"2021120823295659900_R8","unstructured":"Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. New York, NY: Oxford University Press; 1997"},{"key":"2021120823295659900_R9","doi-asserted-by":"crossref","unstructured":"Meltzer MI. Introduction to health economics for physicians. Lancet.\u20082001;358:993\u2013998","DOI":"10.1016\/S0140-6736(01)06107-4"},{"key":"2021120823295659900_R10","unstructured":"Centers for Disease Control and Prevention, Vaccine for Children Program. Pediatric\/VFC vaccine price list. Available at: www.cdc.gov\/vaccines\/programs\/vfc\/cdc-vac-price-list.htm#pediatric. Accessed July 7, 2007"},{"key":"2021120823295659900_R11","doi-asserted-by":"crossref","unstructured":"Jacobs RJ, Margolis HS, Coleman PJ. The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates. Arch Pediatr Adolesc Med.\u20082000;154:763\u2013770","DOI":"10.1001\/archpedi.154.8.763"},{"key":"2021120823295659900_R12","doi-asserted-by":"crossref","unstructured":"Jacobs RJ, Saab S, Meyerhoff AS. The cost effectiveness of hepatitis immunization for US college students. J Am Coll Health.\u20082003;51:227\u2013236","DOI":"10.1080\/07448480309596355"},{"key":"2021120823295659900_R13","doi-asserted-by":"crossref","unstructured":"Bloom BS, Hillman AL, Fendrick AM, Schwartz JS. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis. Ann Intern Med.\u20081993;118:298\u2013306","DOI":"10.7326\/0003-4819-118-4-199302150-00009"},{"key":"2021120823295659900_R14","doi-asserted-by":"crossref","unstructured":"Krahn M, Guasparini R, Sherman M, Detsky AS. Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program. Am J Public Health.\u20081998;88:1638\u20131644","DOI":"10.2105\/AJPH.88.11.1638"},{"key":"2021120823295659900_R15","doi-asserted-by":"crossref","unstructured":"Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization: an economic analysis of current recommendations. JAMA.\u20081995;274:1201\u20131208","DOI":"10.1001\/jama.274.15.1201"},{"key":"2021120823295659900_R16","doi-asserted-by":"crossref","unstructured":"Zhou F, Euler GL, McPhee SJ, et al. Economic analysis of promotion of hepatitis B vaccinations among Vietnamese-American children and adolescents in Houston and Dallas. Pediatrics.\u20082003;111:1289\u20131296","DOI":"10.1542\/peds.111.6.1289"},{"key":"2021120823295659900_R17","doi-asserted-by":"crossref","unstructured":"Deuson RR, Brodovicz KG, Barker L, Zhou F, Euler GL. Economic analysis of a child vaccination project among Asian Americans in Philadelphia, Pa. Arch Pediatr Adolesc Med.\u20082001;155:909\u2013914","DOI":"10.1001\/archpedi.155.8.909"},{"key":"2021120823295659900_R18","doi-asserted-by":"crossref","unstructured":"Averhoff F, Shapiro CN, Bell BP, et al. Control of hepatitis A through routine vaccination of children. JAMA.\u20082001;286:2968\u20132973","DOI":"10.1001\/jama.286.23.2968"},{"key":"2021120823295659900_R19","doi-asserted-by":"crossref","unstructured":"Domi\u0301nguez A, Salleras L, Carmona G, Batalla J. Effectiveness of a mass hepatitis A vaccination program in preadolescents. Vaccine.\u20082003;21:698\u2013701","DOI":"10.1016\/S0264-410X(02)00583-2"},{"key":"2021120823295659900_R20","doi-asserted-by":"crossref","unstructured":"McIntosh ED. Pediatric infections: prevention of transmission and disease: implications for adults. Vaccine.\u20082005;23:2087\u20132089","DOI":"10.1016\/j.vaccine.2005.01.067"},{"key":"2021120823295659900_R21","doi-asserted-by":"crossref","unstructured":"Prosser LA, Bridges CB, Uyeki TM, et al. Health benefits, risks, and cost-effectiveness of influenza vaccination of children. Emerg Infect Dis.\u20082006;12:1548\u20131558","DOI":"10.3201\/eid1210.051015"},{"key":"2021120823295659900_R22","doi-asserted-by":"crossref","unstructured":"Meltzer MI, Neuzil KM, Griffin MR, Fukuda K. An economic analysis of annual influenza vaccination of children. Vaccine.\u20082005;23:1004\u20131014","DOI":"10.1016\/j.vaccine.2004.07.040"},{"key":"2021120823295659900_R23","doi-asserted-by":"crossref","unstructured":"Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis.\u20081999;5:659\u2013671","DOI":"10.3201\/eid0505.990507"},{"key":"2021120823295659900_R24","unstructured":"US Congress, Office of Technology Assessment. Cost Effectiveness of Influenza Vaccination. Washington, DC: US Government Printing Office; 1981"},{"key":"2021120823295659900_R25","doi-asserted-by":"crossref","unstructured":"Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet.\u20082004;364:1757\u20131765","DOI":"10.1016\/S0140-6736(04)17398-4"},{"key":"2021120823295659900_R26","doi-asserted-by":"crossref","unstructured":"Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med.\u20082002;347:1645\u20131651","DOI":"10.1056\/NEJMoa020586"},{"key":"2021120823295659900_R27","unstructured":"Tomson TT, Roden RB, Wu TC. Human papillomavirus vaccines for the prevention and treatment of cervical cancer. Curr Opin Investig Drugs.\u20082004;5:1247\u20131261"},{"key":"2021120823295659900_R28","doi-asserted-by":"crossref","unstructured":"Simon P. Progress towards a vaccine for cervical cancer. Curr Opin Obstet Gynecol.\u20082005;17:65\u201370","DOI":"10.1097\/00001703-200502000-00012"},{"key":"2021120823295659900_R29","doi-asserted-by":"crossref","unstructured":"Stern PL. Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. J Clin Virol.\u20082005;32(suppl 1):72\u201381","DOI":"10.1016\/j.jcv.2004.12.005"},{"key":"2021120823295659900_R30","doi-asserted-by":"crossref","unstructured":"Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep.\u20082007;56(RR-2):1\u201324","DOI":"10.1037\/e601292007-001"},{"key":"2021120823295659900_R31","doi-asserted-by":"crossref","unstructured":"Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA.\u20082003;290:781\u2013789","DOI":"10.1001\/jama.290.6.781"},{"key":"2021120823295659900_R32","doi-asserted-by":"crossref","unstructured":"Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis.\u20082004;10:1915\u20131923","DOI":"10.3201\/eid1011.040222"},{"key":"2021120823295659900_R33","doi-asserted-by":"crossref","unstructured":"Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis.\u20082003;9:37\u201348","DOI":"10.3201\/eid0901.020168"},{"key":"2021120823295659900_R34","doi-asserted-by":"crossref","unstructured":"Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology.\u20082002;13:631\u2013639","DOI":"10.1097\/00001648-200211000-00006"},{"key":"2021120823295659900_R35","doi-asserted-by":"crossref","unstructured":"Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16\/18 vaccine. J Natl Cancer Inst.\u20082004;96:604\u2013615","DOI":"10.1093\/jnci\/djh104"},{"key":"2021120823295659900_R36","unstructured":"Institute of Medicine. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: National Academy of Sciences; 2000"},{"key":"2021120823295659900_R37","doi-asserted-by":"crossref","unstructured":"Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med.\u20082001;344:1378\u20131388","DOI":"10.1056\/NEJM200105033441807"},{"key":"2021120823295659900_R38","unstructured":"Bilukha OO, Rosenstein N; National Center for Infectious Diseases, Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep.\u20082005;54(RR-7):1\u201321"},{"key":"2021120823295659900_R39","doi-asserted-by":"crossref","unstructured":"Shepard CW, Ortega-Sanchez IR, Scott RD 2nd, Rosenstein NE; ABCs Team. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics.\u20082005;115:1220\u20131232","DOI":"10.1542\/peds.2004-2514"},{"key":"2021120823295659900_R40","doi-asserted-by":"crossref","unstructured":"Scott RD 2nd, Meltzer MI, Erickson LJ, De Wals P, Rosenstein NE. Vaccinating first-year college students living in dormitories for Meningococcal disease: an economic analysis. Am J Prev Med.\u20082002;23:98\u2013105","DOI":"10.1016\/S0749-3797(02)00462-2"},{"key":"2021120823295659900_R41","doi-asserted-by":"crossref","unstructured":"Ortega-Sanchez IR, Meltzer MI, Shepard CW, et al. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the US. Clin Infect Dis.\u20082008;46: In press","DOI":"10.1086\/524041"},{"key":"2021120823295659900_R42","doi-asserted-by":"crossref","unstructured":"Raghunathan PL, Bernhardt SA, Rosenstein NE. Opportunities for control of meningococcal disease in the United States. Annu Rev Med.\u20082004;55:333\u2013353","DOI":"10.1146\/annurev.med.55.091902.103612"},{"key":"2021120823295659900_R43","doi-asserted-by":"crossref","unstructured":"Imrey PB, Jackson LA, Ludwinski PH, et al. Outbreak of serogroup C meningococcal disease associated with campus bar patronage. Am J Epidemiol.\u20081996;143:624\u2013630","DOI":"10.1093\/oxfordjournals.aje.a008792"},{"key":"2021120823295659900_R44","doi-asserted-by":"crossref","unstructured":"Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ.\u20082003;326:365\u2013366","DOI":"10.1136\/bmj.326.7385.365"},{"key":"2021120823295659900_R45","unstructured":"Kretsinger K, Broder KR, Cortese MM, et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine\u2014recommendations of the Advisory Committee on Immunization Practices, supported by the Healthcare Infection Control Practices Advisory Committee for use of Tdap among health-care personnel. MMWR Recomm Rep.\u20082006;55(RR-17):1\u201337"},{"key":"2021120823295659900_R46","doi-asserted-by":"crossref","unstructured":"Iskedjian M, Walker JH, Hemels ME. Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada. Vaccine.\u20082004;22:4215\u20134227","DOI":"10.1016\/j.vaccine.2004.04.025"},{"key":"2021120823295659900_R47","doi-asserted-by":"crossref","unstructured":"Purdy KW, Hay JW, Botteman MF, Ward JI. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis.\u20082004;39:20\u201328","DOI":"10.1086\/421091"},{"key":"2021120823295659900_R48","doi-asserted-by":"crossref","unstructured":"Lee GM, Lebaron C, Murphy TV, Lett S, Schauer S, Lieu TA. Pertussis in adolescents and adults: should we vaccinate?Pediatrics.\u20082005;115:1675\u20131684","DOI":"10.1542\/peds.2004-2509"},{"key":"2021120823295659900_R49","doi-asserted-by":"crossref","unstructured":"Caro JJ, Getsios D, El Hadi W, Payne K, O'brien JA. Pertussis immunization of adolescents in the united states: an economic evaluation. Pediatr Infect Dis J.\u20082005;24:S75\u2013S82","DOI":"10.1097\/01.inf.0000160918.72953.51"},{"key":"2021120823295659900_R50","doi-asserted-by":"crossref","unstructured":"Lee GM, Lett S, Schauer S, et al. Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis.\u20082004;39:1572\u20131580","DOI":"10.1086\/425006"},{"key":"2021120823295659900_R51","doi-asserted-by":"crossref","unstructured":"Van Rie A, Hethcote HW. Adolescent and adult pertussis vaccination: computer simulations of five new strategies. Vaccine.\u20082004;22:3154\u20133165","DOI":"10.1016\/j.vaccine.2004.01.067"},{"key":"2021120823295659900_R52","doi-asserted-by":"crossref","unstructured":"Lieu TA, Ray G, Black SB, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA.\u20082000;283:1460\u20131468","DOI":"10.1001\/jama.283.11.1460"},{"key":"2021120823295659900_R53","doi-asserted-by":"crossref","unstructured":"Strassels SA, Sullivan SD. Clinical and economic considerations of vaccination against varicella. Pharmacotherapy.\u20081997;17:133\u2013139","DOI":"10.1002\/j.1875-9114.1997.tb03686.x"},{"key":"2021120823295659900_R54","unstructured":"Centers for Disease Control and Prevention. Vaccination coverage among children entering school: United States, 2003\u201304 School Year. MMWR Morb Mortal Wkly Rep.\u20082004;53:1041\u20131044"},{"key":"2021120823295659900_R55","doi-asserted-by":"crossref","unstructured":"Grosse SD, Teutsch SM, Haddix AC. Lessons from cost-effectiveness research for United States public health policy. Annu Rev Public Health.\u20082007;28:365\u2013391","DOI":"10.1146\/annurev.publhealth.28.021406.144046"},{"key":"2021120823295659900_R56","unstructured":"Miller TR. Variations between countries in values of statistical life. J Trans Econ Policy.\u20082000;34:169\u2013188"},{"key":"2021120823295659900_R57","doi-asserted-by":"crossref","unstructured":"Viscusi WK, Aldy JE. The value of statistical life: a critical review of market estimates throughout the world. J Risk Uncertain.\u20082003;27:5\u201376","DOI":"10.3386\/w9487"},{"key":"2021120823295659900_R58","doi-asserted-by":"crossref","unstructured":"Gyrd-Hansen D. Willingness to pay for a QALY: theoretical and methodological issues. Pharmacoeconomics.\u20082005;23:423\u2013432","DOI":"10.2165\/00019053-200523050-00002"},{"key":"2021120823295659900_R59","doi-asserted-by":"crossref","unstructured":"Wang LY, Yang Q, Lowry R, Wechsler H. Economic analysis of a school-based obesity prevention program. Obes Res.\u20082003;11:1313\u20131324","DOI":"10.1038\/oby.2003.178"},{"key":"2021120823295659900_R60","unstructured":"Miller TR, Finkelstein EA, Zaloshnja E, Hendrie D. The cost of child and adolescent injuries and the savings from prevention, In: Liller K, ed. Injury Prevention for Children and Adolescents: Research, Practice, and Advocacy, Washington DC: American Public Health Association; 2005:15\u201364"},{"key":"2021120823295659900_R61","doi-asserted-by":"crossref","unstructured":"Broder KR, Cohn AC, Schwartz B, et al. Adolescent immunizations and other clinical preventive services: a needle and a hook?Pediatrics.\u20082008;121:S25\u2013S34","DOI":"10.1542\/peds.2007-1115D"},{"key":"2021120823295659900_R62","doi-asserted-by":"crossref","unstructured":"Szilagyi P, Rand CM, McLaurin J, et al. Delivering adolescent vaccinations in the medical home: a new era?Pediatrics.\u20082008;121:S15\u2013S24","DOI":"10.1542\/peds.2007-1115C"},{"key":"2021120823295659900_R63","doi-asserted-by":"crossref","unstructured":"Lee GM, Salomon JA, LeBaron CW, Lieu TA. Health-state valuations for pertussis: methods for valuing short-term health states. Health Qual Life Outcomes.\u20082005;3:17","DOI":"10.1186\/1477-7525-3-17"},{"key":"2021120823295659900_R64","doi-asserted-by":"crossref","unstructured":"Griebsch I, Coast J, Brown J. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. Pediatrics.\u20082005;115(5). Available at: www.pediatrics.org\/cgi\/content\/full\/115\/5\/e600","DOI":"10.1542\/peds.2004-2127"},{"key":"2021120823295659900_R65","doi-asserted-by":"crossref","unstructured":"Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russel L. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA.\u20081996;276:1253\u20131258","DOI":"10.1001\/jama.276.15.1253"},{"key":"2021120823295659900_R66","doi-asserted-by":"crossref","unstructured":"Blumstein JF. The Oregon experiment: the role of cost-benefit analysis in the allocation of Medicaid funds. Soc Sci Med.\u20081997;45:545\u2013554","DOI":"10.1016\/S0277-9536(96)00395-4"},{"key":"2021120823295659900_R67","unstructured":"Edgar A, Salek S, Shickle D, Cohen D. The Ethical QALY: Ethical Issues in Healthcare Resource Allocations. Haslemere, England: Euromed Communications; 1998"},{"key":"2021120823295659900_R68","unstructured":"Centers for Disease Control and Prevention. Immunization of adolescents: recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians, and the American Medical Association. MMWR Recomm Rep.\u20081996;45(RR-13):1\u201316"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/Supplement_1\/S63\/1003718\/zpe10108000s63.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/Supplement_1\/S63\/1003718\/zpe10108000s63.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T01:16:29Z","timestamp":1708478189000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/121\/Supplement_1\/S63\/70132\/Projected-Cost-effectiveness-of-New-Vaccines-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,1]]},"references-count":68,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2008,1,1]]},"published-print":{"date-parts":[[2008,1,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2007-1115h","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"type":"print","value":"0031-4005"},{"type":"electronic","value":"1098-4275"}],"subject":[],"published":{"date-parts":[[2008,1,1]]}}}